ES2068334T3 - Derivados 3-sustituidos de 2-oxindoles como agentes antiinflamatorios. - Google Patents

Derivados 3-sustituidos de 2-oxindoles como agentes antiinflamatorios.

Info

Publication number
ES2068334T3
ES2068334T3 ES90303992T ES90303992T ES2068334T3 ES 2068334 T3 ES2068334 T3 ES 2068334T3 ES 90303992 T ES90303992 T ES 90303992T ES 90303992 T ES90303992 T ES 90303992T ES 2068334 T3 ES2068334 T3 ES 2068334T3
Authority
ES
Spain
Prior art keywords
derivatives
interleukin
relative
oxydoles
substituted derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90303992T
Other languages
English (en)
Inventor
Frederick Jacob Ehrgott
Gary Richard Schulte
Carl Joseph Goddard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of ES2068334T3 publication Critical patent/ES2068334T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Abstract

ESTA INVENCION ES RELATIVA A NUEVOS DERIVADOS DE 2-INDOFENOL 3-SUSTITUIDOS, LOS CUALES SON INHIBIDORES DE BIOSINTESIS DE SINTASA PROSTAGLANDINA H2, 5-LIPOOXIGENASA E INTERLEUKIN-1. LOS COMPUESTOS DE LA INVENCION SE USAN COMO INHIBIDORES DE BIOSINTESIS DE SINTASA PROSTAGLANDINA H2 E INTERLEUKIN-1, POR SI MISMOS, Y COMO AGENTES ANALGESICOS, ANTI-INFLAMATORIOS Y ANTI-ARTRITICOS, EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS CRONICAS. ESTA INVENCION TAMBIEN ES RELATIVA A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS DERIVADOS, A METODOS DE INHIBIR SINTASA PROSTAGLANDINA H2 Y LA BIOSINTESIS DE INTERLEUKIN-1, Y AL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS CRONICAS EN UN MAMIFERO CON DICHOS COMPUESTOS. ADEMAS, ESTA INVENCION ES RELATIVA A CIERTOS NUEVOS ACIDOS CARBOXILICOS USADOS COMO PRODUCTOS INTERMEDIOS EN LA PREPARACION DE LOS DERIVADOS 2-INDOFENOL 3-SUSTITUIDOS DE ESTA INVENCION Y A UN PROCESO PARA LA PREPARACION DE LOS DERIVADOS 2-INDOFENOL 3-SUSTITUIDOS.
ES90303992T 1989-04-18 1990-04-12 Derivados 3-sustituidos de 2-oxindoles como agentes antiinflamatorios. Expired - Lifetime ES2068334T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34011389A 1989-04-18 1989-04-18

Publications (1)

Publication Number Publication Date
ES2068334T3 true ES2068334T3 (es) 1995-04-16

Family

ID=23331948

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90303992T Expired - Lifetime ES2068334T3 (es) 1989-04-18 1990-04-12 Derivados 3-sustituidos de 2-oxindoles como agentes antiinflamatorios.

Country Status (33)

Country Link
US (4) US5047554A (es)
EP (1) EP0393936B1 (es)
JP (2) JP2506478B2 (es)
KR (1) KR920006394B1 (es)
CN (1) CN1022832C (es)
AP (1) AP142A (es)
AT (1) ATE118767T1 (es)
AU (1) AU633767B2 (es)
BG (1) BG60646B1 (es)
CA (1) CA2014467C (es)
CZ (1) CZ284340B6 (es)
DD (1) DD293822A5 (es)
DE (1) DE69017066T2 (es)
DK (1) DK0393936T3 (es)
EG (1) EG19122A (es)
ES (1) ES2068334T3 (es)
FI (1) FI106378B (es)
GR (1) GR3015811T3 (es)
HU (2) HUT58314A (es)
IE (1) IE65091B1 (es)
IL (3) IL110173A (es)
IS (1) IS1636B (es)
MA (1) MA21808A1 (es)
MX (1) MX20359A (es)
NO (1) NO176759C (es)
NZ (1) NZ233320A (es)
OA (1) OA09205A (es)
PL (2) PL163951B1 (es)
PT (1) PT93785B (es)
RO (1) RO106402B1 (es)
RU (2) RU2039042C1 (es)
YU (1) YU47588B (es)
ZA (1) ZA902871B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990004393A1 (en) * 1988-10-18 1990-05-03 Pfizer Inc. Prodrugs of antiinflammatory 3-acyl-2-oxindole-1-carboxamides
ES2075055T3 (es) * 1988-10-18 1995-10-01 Pfizer Profarmacos de 3-acil-2-oxindol-1-carboxamidas antiinflamatorias.
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives
IL95880A (en) * 1989-10-13 1995-12-31 Pfizer Use of 3-Transformed History of 2-Oxindole for the Preparation of Pharmaceuticals for Inhibition of Interlaukio-1 Biosynthesis
US5064851A (en) * 1990-07-24 1991-11-12 Pfizer Inc. 3-(1-substituted-pyrazoyl)-2-oxindole derivatives, compositions and use
TW438798B (en) * 1992-10-07 2001-06-07 Pfizer 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions
NZ256279A (en) * 1992-11-23 1996-11-26 Pfizer 4-chloro-5-trihydrocarbylsilylthiophene-2-carboxylic acids, dimers, preparation of a 4-chloro-2-thiophene carboxylic acid and 5-fluoro-6-chloro-3-(4-chloro-2-thenoyl)-2-oxindole- 1-carboxamide
US5298522A (en) * 1993-01-22 1994-03-29 Pfizer Inc. 6-chloro-5-fluoro-3-(2-thenoyl)-2-oxindole-1-carboxamide as an analgesic and anti-inflammatory agent while maintaining a normal urine protein/creatinine ratio
DE69305999T2 (de) * 1993-02-09 1997-03-06 Pfizer Oxindol 1-[n-(alkoxycarbonyl)]carboxamide und 1-[n-carboxamido]carboxamide als antiinflammatorische wirkstoffe
ES2076106B1 (es) * 1993-08-26 1996-06-16 Pfizer Composiciones farmaceuticas a base de 2-oxindol-1-carboxamidas 3-sustituidas
US5783664A (en) * 1993-09-17 1998-07-21 Smithkline Beecham Corporation Cytokine suppressive anit-inflammatory drug binding proteins
EP0679396A1 (en) * 1994-03-02 1995-11-02 Pfizer Inc. Use of 3-substituted-2-oxidole-1-carboxamides for the manufacture of a medicament in the treatment and prevention of ischemia induced myocardial injury and cytokine mediated myocardial injury
CN1051452C (zh) * 1994-07-26 2000-04-19 中国医学科学院血液学研究所 3-取代芳基氧化吲哚类化合物的应用
US5545656A (en) * 1995-04-05 1996-08-13 Pfizer Inc. 2-Oxidole-1-carboxamide pharmaceutical agents for the treatment of alzheimer's disease
AU7503496A (en) * 1995-12-19 1997-07-14 Pfizer Inc. Stable, long acting salts of indole derivatives for the treatment of joint diseases
EP0826685A1 (en) * 1996-08-21 1998-03-04 Pfizer Inc. Stable, long acting salts of carboxamides for the treatment of joint disease
US6043379A (en) * 1997-04-04 2000-03-28 Pfizer Inc. Processes and intermediates for preparing 2-fluorothiophene derivatives
US6291514B1 (en) 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
US6649645B1 (en) 1998-12-23 2003-11-18 Pharmacia Corporation Combination therapy of radiation and a COX-2 inhibitor for treatment of neoplasia
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
EP1255752B1 (en) * 2000-02-15 2007-08-08 Sugen, Inc. Pyrrole substituted 2-indolinone protein kinase inhibitors
AU2002230056A1 (en) * 2001-01-29 2002-08-12 Insight Strategy And Marketing Ltd Indole derivatives and their uses as heparanase inhibitors
AR042586A1 (es) * 2001-02-15 2005-06-29 Sugen Inc 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa
JP2004529110A (ja) * 2001-03-06 2004-09-24 アストラゼネカ アクチボラグ 脈管損傷活性を有するインドール誘導体
EP1434774A1 (en) 2001-10-10 2004-07-07 Sugen, Inc. 3-(4-substituted heterocyclyl)-pyrrol-2-ylmethylidene)-2-indolinone derivatives as protein kinase inhibitors
WO2003089427A1 (en) 2002-04-22 2003-10-30 Pfizer Products Inc. Indol-2-ones as selective inhibitors of cyclooxygenase-2
ES2600460T3 (es) 2005-05-10 2017-02-09 Intermune, Inc. Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés
CA2696609C (en) 2007-08-27 2017-09-05 Helicon Therapeutics, Inc. Therapeutic isoxazole compounds
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
NZ771180A (en) 2009-04-29 2022-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US8933248B2 (en) 2012-06-21 2015-01-13 Council Of Scientific & Industrial Research 3-substituted-3-hydroxy oxindole derivatives and process for preparation thereof
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CN110452216B (zh) 2014-04-02 2022-08-26 英特穆恩公司 抗纤维化吡啶酮类
UA121116C2 (uk) 2014-06-06 2020-04-10 Басф Се Застосування заміщених оксадіазолів для боротьби з фітопатогенними грибами
WO2016150937A1 (en) 2015-03-25 2016-09-29 Lonza Ltd Method for preparation of thiophenecarbonyl chlorides
BR112018009539B1 (pt) 2015-11-13 2022-05-24 Basf Se Uso de compostos da fórmula i, compostos, mistura, composição agroquímica, uso dos compostos e método para combater fungos nocivos fitopatogênicos
AR106679A1 (es) 2015-11-13 2018-02-07 Basf Se Oxadiazoles sustituidos para combatir hongos fitopatógenos
EA201891146A1 (ru) 2015-11-19 2018-12-28 Басф Се Замещенные оксадиазолы для борьбы с фитопатогенными грибами
RU2018138748A (ru) 2016-04-11 2020-05-12 Басф Се Замещенные оксадиазолы для борьбы с фитопатогенными грибами
CN108299354A (zh) * 2017-01-12 2018-07-20 中国科学院宁波材料技术与工程研究所 一种2,5-呋喃二甲酸或其酯化物的制备方法
CN115403566B (zh) * 2022-09-21 2024-01-30 山东大学 3-取代吲哚-2-酮化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1255658A (en) * 1917-11-12 1918-02-05 Adamson Stephens Mfg Co Carrier for belt conveyers.
BE756447A (fr) * 1969-10-15 1971-03-22 Pfizer Oxindolecarboxamides
US3900563A (en) * 1973-06-18 1975-08-19 American Cyanamid Co Method of using 3-(2-(4-phenyl-1-piperazinyl)ethyl)-indolines
US4721712A (en) * 1984-06-12 1988-01-26 Pfizer Inc. 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
US4556672A (en) * 1984-03-19 1985-12-03 Pfizer Inc. 3-Substituted 2-oxindole-1-carboxamides as analgesic and anti-inflammatory agents
IN162090B (es) * 1984-03-19 1988-03-26 Pfizer
US4569942A (en) * 1984-05-04 1986-02-11 Pfizer Inc. N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and antiinflammatory agents
IN161509B (es) * 1984-05-04 1987-12-19 Pfizer
WO1986001510A1 (en) * 1984-08-24 1986-03-13 Pfizer Inc. Tricyclic oxindole antiinflammatory agents
FI80270C (fi) * 1984-09-19 1990-05-10 Pfizer Foerfarande foer framstaellning av analgetiska och anti-inflammatoriska 1,3-diacyl-2-oxoindol-foereningar och mellanprodukter.
US4808601A (en) * 1984-09-19 1989-02-28 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4690943A (en) * 1984-09-19 1987-09-01 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
US4752609A (en) * 1985-06-20 1988-06-21 Pfizer Inc. Analgesic and antiinflammatory 1,3-diacyl-2-oxindole compounds
EP0409825A1 (en) * 1986-11-14 1991-01-30 HERMAS, Kalervo Alfred August Lens for receiving and/or transmitting infrared radiation
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US4861794A (en) * 1988-04-13 1989-08-29 Pfizer Inc. 3-substituted-2-oxindole-1-carboxamides as inhibitors of interleukin-1 biosynthesis
US5047554A (en) * 1989-04-18 1991-09-10 Pfizer Inc. 3-substituted-2-oxindole derivatives

Also Published As

Publication number Publication date
PT93785B (pt) 1996-09-30
FI106378B (fi) 2001-01-31
IL94047A0 (en) 1991-01-31
EG19122A (en) 1994-07-30
EP0393936A1 (en) 1990-10-24
RO106402B1 (ro) 1993-04-30
NO176759B (no) 1995-02-13
YU47588B (sh) 1995-10-24
HU902462D0 (en) 1990-08-28
PL287812A1 (en) 1991-07-15
HUT58314A (en) 1992-02-28
HU211150A9 (en) 1995-10-30
US5919809A (en) 1999-07-06
US6174883B1 (en) 2001-01-16
GR3015811T3 (en) 1995-07-31
FI901915A0 (fi) 1990-04-17
IS1636B (is) 1996-09-20
DK0393936T3 (da) 1995-06-26
DE69017066T2 (de) 1995-06-14
PL284817A1 (en) 1991-03-25
PL163941B1 (pl) 1994-05-31
IS3570A7 (is) 1990-10-19
DD293822A5 (de) 1991-09-12
IE901360L (en) 1990-10-18
AP9000175A0 (en) 1990-04-30
YU75590A (sh) 1992-07-20
BG60646B1 (bg) 1995-11-30
PT93785A (pt) 1990-11-20
MA21808A1 (fr) 1990-12-31
MX20359A (es) 1994-02-28
AU1051092A (en) 1992-04-09
RU2073671C1 (ru) 1997-02-20
CA2014467C (en) 2000-02-08
IE65091B1 (en) 1995-10-04
ZA902871B (en) 1991-11-27
NO901684D0 (no) 1990-04-17
OA09205A (en) 1992-06-30
NZ233320A (en) 1991-09-25
CZ184890A3 (cs) 1998-07-15
JP2581525B2 (ja) 1997-02-12
AU621477B2 (en) 1992-03-12
IL94047A (en) 1995-10-31
US5047554A (en) 1991-09-10
NO176759C (no) 1995-05-24
NO901684L (no) 1990-10-19
IL110173A0 (en) 1994-10-07
ATE118767T1 (de) 1995-03-15
CN1046525A (zh) 1990-10-31
EP0393936B1 (en) 1995-02-22
JP2506478B2 (ja) 1996-06-12
RU2039042C1 (ru) 1995-07-09
CZ284340B6 (cs) 1998-10-14
AP142A (en) 1991-09-26
IL110173A (en) 1997-06-10
DE69017066D1 (de) 1995-03-30
CN1022832C (zh) 1993-11-24
US5290802A (en) 1994-03-01
AU5362690A (en) 1990-11-22
AU633767B2 (en) 1993-02-04
JPH02292258A (ja) 1990-12-03
KR920006394B1 (ko) 1992-08-06
KR900016189A (ko) 1990-11-12
CA2014467A1 (en) 1990-10-18
JPH07118261A (ja) 1995-05-09
PL163951B1 (pl) 1994-05-31

Similar Documents

Publication Publication Date Title
ES2068334T3 (es) Derivados 3-sustituidos de 2-oxindoles como agentes antiinflamatorios.
Claria et al. Aspirin-triggered lipoxins (15-epi-LX) are generated by the human lung adenocarcinoma cell line (A549)–neutrophil interactions and are potent inhibitors of cell proliferation
AR012264A1 (es) Compuesto, composicion farmaceutica y metodo para obtener la composicion para prevenir o evitar una enfermedad asociada a actividad metaloproteasicaindeseada
ES2130452T3 (es) Derivados de ciclobutano utilizados como inhibidores de la escualeno-sintetasa y de la farnesiltransferasa proteica.
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
ES2136037B1 (es) Inhibidores de sulfamida-metaloproteasa
EA200000358A1 (ru) Способ получения диарилпиридинов, полезных в качестве ингибиторов cox-2
AR009358A1 (es) Compuesto espirociclico inhibidor de la metaloproteasa
Rao et al. Neuroprotection by group I metabotropic glutamate receptor antagonists in forebrain ischemia of gerbil
ES2187675T3 (es) (metilsulfonil)fenil-2-(5h)-furanonas como inhibidores de cox-2.
IT1254915B (it) Derivati di adenosina ad attivita' a2 agonista
MX9404749A (es) Heterociclos de fenilo como inhibidores de cox-2.
BR9909597A (pt) Composto, composição farmacêutica e método de tratamento de câncer e doenças proliferativas
AR126101A1 (es) Heterociclos tricíclicos como inhibidores de fgfr
DK0656001T3 (da) Nye 2-substituerede indan-2-mercaptoacetylamid-tricycliske derivater til anvendelse som enkefalinasehæmmere
EA199800155A1 (ru) Новое соединение
AR016382A1 (es) Uso de un derivado del acido bencil-indazol metoxialcanoico.
ES2058186T3 (es) Procedimiento para la fabricacion de acidos quinoloncarboxilicos.
EA199900948A1 (ru) Способ получения 2-арил-3-арил-5-галогенпиридинов, используемых в качестве ингибиторов cox-2
EA199901043A1 (ru) ИНГИБИТОРЫ ФАРНЕЗИЛТРАНСФЕРАЗЫ В КОМБИНАЦИИ С ИНГИБИТОРАМИ HMG-CoA-РЕДУКТАЗЫ ДЛЯ ЛЕЧЕНИЯ РАКА
NO983511D0 (no) Difenylstilbener som pro-legemidler for COX-2-inhibitorer
ATE141601T1 (de) 3-(1-substituierte pyrazoyl)-2-oxindolderivate
ES2122221T3 (es) Compuestos terapeuticos adecuados para el tratamiento de enfermedades conectadas con la deficiencia de glutation, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
ATE239739T1 (de) Phospholipid-derivate von nichtsteroiden entzündungshemmenden medikamenten
ES2169399T3 (es) Procedimiento para preparar heterociclos de fenilo utiles como inhibidores de la cox-2.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 393936

Country of ref document: ES